Overview

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab